Lifevantage (NASDAQ:LFVN) Stock Price Passes Below 200-Day Moving Average – Time to Sell?

Lifevantage Corporation (NASDAQ:LFVN)’s stock price crossed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $9.54 and traded as low as $6.09. Lifevantage shares last traded at $6.34, with a volume of 175,913 shares changing hands.

Analyst Upgrades and Downgrades

LFVN has been the topic of several analyst reports. Lake Street Capital reissued a “buy” rating and issued a $12.00 price objective on shares of Lifevantage in a research note on Wednesday, November 5th. Wall Street Zen cut Lifevantage from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Lifevantage in a report on Monday, December 29th. One research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, Lifevantage presently has an average rating of “Moderate Buy” and an average price target of $12.00.

Lifevantage Price Performance

The company has a market capitalization of $80.52 million, a P/E ratio of 8.23 and a beta of 0.34. The firm’s 50-day moving average is $6.42 and its 200-day moving average is $9.54.

Lifevantage (NASDAQ:LFVN) last released its quarterly earnings data on Tuesday, November 4th. The company reported $0.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.17 by $0.01. Lifevantage had a net margin of 4.43% and a return on equity of 33.52%. The firm had revenue of $47.56 million for the quarter, compared to analysts’ expectations of $54.74 million. Lifevantage has set its FY 2026 guidance at 1.000-1.150 EPS.

Lifevantage Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, December 15th. Stockholders of record on Monday, December 1st were given a dividend of $0.045 per share. The ex-dividend date of this dividend was Monday, December 1st. This represents a $0.18 dividend on an annualized basis and a dividend yield of 2.8%. Lifevantage’s dividend payout ratio is presently 23.38%.

Insiders Place Their Bets

In other Lifevantage news, Director Michael A. Beindorff sold 12,607 shares of Lifevantage stock in a transaction dated Wednesday, November 19th. The stock was sold at an average price of $6.42, for a total value of $80,936.94. Following the transaction, the director owned 43,806 shares in the company, valued at $281,234.52. The trade was a 22.35% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders sold a total of 48,607 shares of company stock worth $330,467 over the last 90 days. 21.95% of the stock is owned by company insiders.

Hedge Funds Weigh In On Lifevantage

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LFVN. Cubist Systematic Strategies LLC purchased a new position in Lifevantage during the first quarter valued at approximately $97,000. Jones Financial Companies Lllp raised its stake in shares of Lifevantage by 14,484.0% in the first quarter. Jones Financial Companies Lllp now owns 29,168 shares of the company’s stock valued at $425,000 after acquiring an additional 28,968 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in Lifevantage by 24.5% in the first quarter. Goldman Sachs Group Inc. now owns 44,518 shares of the company’s stock valued at $649,000 after buying an additional 8,762 shares in the last quarter. Jane Street Group LLC lifted its holdings in shares of Lifevantage by 5.4% in the 1st quarter. Jane Street Group LLC now owns 36,567 shares of the company’s stock valued at $533,000 after purchasing an additional 1,877 shares during the last quarter. Finally, Farther Finance Advisors LLC acquired a new stake in Lifevantage during the 2nd quarter worth approximately $25,000. Hedge funds and other institutional investors own 35.32% of the company’s stock.

About Lifevantage

LifeVantage Corporation is a publicly traded company that develops, markets and distributes nutritional supplements, skincare products and weight-management solutions through a direct-selling business model. The company’s flagship offering, Protandim®, is formulated to activate the Nrf2 pathway, which is associated with cellular defense processes. LifeVantage also markets the PhysIQ® line for metabolism and body composition support and the TrueScience® skincare regimen, targeting a range of health and wellness needs.

Founded in 1999 and headquartered in Sandy, Utah, LifeVantage combines research in nutrigenomics with a network of independent distributors to bring its products to market.